J&J files for authorization of Covid-19 vaccine booster shot
[ad_1]
A nurse fills a syringe with Johnson & Johnson’s Janssen Covid-19 vaccine at a clinic hosted by The Tournament of Roses in partnership with the Pasadena Public Health Department, August 19, 2021 at Tournament House in Pasadena, California.
Robyn Beck | AFP | Getty Images
Johnson & JohnsonIt said Tuesday that it submitted data to U.S. Food and Drug Administration in order to obtain emergency authorization for a booster shot of Covid-19 vaccine in persons aged 18 and over.
The filing comes after the FDA last week scheduled an Oct. 15 meeting of its expert advisory committee to discuss whether to authorize a second shot of J&J’s single-dose vaccine.
J&J said its submission includes data from a late-stage study that found a booster of its vaccine given 56 days after the primary dose provided 94% protection against symptomatic Covid-19 in the United States and 100% protection against severe disease, at least 14 days after the booster shot.
FDA already approved the approval of a booster dose for the vaccine. PfizerPartner BioNTechFor 65 years and over, those at highest risk for severe diseases and people who have been exposed regularly to the virus are considered high-risk.
This is a developing story. Stay tuned for new updates.
[ad_2]